Boti
AcquiredFounded 2015 · $27.2M raised
- Employees
- 1–10
- Founded
- 2015
- Business Model
- B2B
- Total Funding
- $27.2M
- Last Round
- $15.5M Series CJan 2018
- Rounds
- 2
- Acquisition Date
- Sep 2018
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
About
Bonti, Inc. was a Newport Beach, California-based clinical-stage biotechnology company founded in 2015 that developed EB-001, a fast-acting, short-duration botulinum neurotoxin of serotype E for cosmetic and therapeutic use, positioned as an alternative to longer-lasting neuromodulators like Botox. The company raised roughly $36 million in funding before Allergan plc acquired it in October 2018 for $195 million upfront, adding new neurotoxin programs to Allergan's medical aesthetics pipeline.
Summary
Boti is a Biotech company, founded in 2015. It has raised $27.2M in total across 2 rounds, most recently a $15.5M Series C round in Jan 2018. Investors include HighLight Capital.
Funding & Exit History
Sep 2018
Sign up to see all 3 events
Funding: Series B through Series C. Amounts, valuations, and investors where available.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Integrated biopharmaceutical solutions company
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/boti"><img src="https://indexed.vc/api/badge/company/boti" alt="Boti on Indexed.vc" width="260" height="76" /></a>